|Bid||327.74 x 1000|
|Ask||328.01 x 1100|
|Day's Range||324.35 - 336.51|
|52 Week Range||250.21 - 351.86|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||35.81|
|Earnings Date||Jul 22, 2020 - Jul 27, 2020|
|Forward Dividend & Yield||0.88 (0.26%)|
|Ex-Dividend Date||Jun 12, 2020|
|1y Target Est||357.13|
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will provide online programming and virtual exhibits to introduce scientists to a number of new products that build on its leading Orbitrap platform and expand research applications.
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives.
In this article we will take a look at whether hedge funds think Thermo Fisher Scientific Inc. (NYSE:TMO) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get […]
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per common share, payable on July 15, 2020, to shareholders of record as of June 15, 2020.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has received a contract from the U.S. government to provide highly specialized viral transport media (VTM) for COVID-19 sample collection. The VTM is used during collection of patient samples for proper transport to laboratories that can test for the presence of the virus.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published the offer document (the "Offer Document") for its voluntary tender offer (the "Tender Offer") for all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) at an offer price of €39 per share in cash, following approval of the publication by the German Federal Financial Supervisory Authority.
Thermo Fisher Scientific today released the Thermo Scientific Helios 5 Laser PFIB system, an advanced focused ion beam scanning electron microscope (FIB-SEM) with a fully integrated femtosecond laser that quickly characterizes millimeter-scale volumes of material in 3D with nanometer resolution.
Sanofi Chief Executive Paul Hudson reportedly said Wednesday the U.S. will have first access to its coronavirus vaccine. Thermo Fisher also announced expanded coronavirus testing.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced it will expand its response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic. The new test is the result of ongoing collaboration between all three organizations, including clinical evaluation and support from Mayo Clinic. Thermo Fisher will seek U.S. FDA Emergency Use Authorization (EUA) and international regulatory authorizations for the test over the next few weeks.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has further expanded emergency use authorization (EUA) for its multiplex real-time PCR test intended for the qualitative detection of nucleic acid from SARS‑CoV‑2, the virus that causes COVID-19.
German molecular testing company Qiagen plans a 50-fold increase in production of viral RNA extraction kits to meet rising demand for products used in COVID-19 testing, the company said on Wednesday. Qiagen began shipping a rapid diagnostic test for COVID-19, which requires less than one minute for sample preparation and can deliver results in about one hour, to the United States in late March. The company is also carrying out research to develop further solutions for detection of the new coronavirus, tools for research into potential vaccines and treatments as well as new serology tests for antibodies, Chief Executive Thierry Bernard said in a statement.
There are still unanswered questions about the accuracy of some COVID-19 tests, the prevalence of antibodies among Americans, and whether those antibodies provide the kind of immunity safety net needed to protect people from future infections.
Shares of TMO stock neared a buy point Wednesday after Thermo Fisher Scientific topped first-quarter earnings expectations. Sales missed some expectations, though beat others.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.
Thermo Fisher (TMO) delivered earnings and revenue surprises of 5.38% and 0.38%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / April 22, 2020 / Thermo Fisher Scientific, Inc. (NYSE:TMO) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 22, 2020 at ...
Shares of Thermo Fisher Scientific (NYSE:TMO) rose 1.2% in pre-market trading after the company reported upbeat Q1 results.Quarterly Results Earnings per share increased 4.63% over the past year to $2.94, which beat the estimate of $2.79.Revenue of $6,230,000,000 up by 1.71% from the same period last year, which beat the estimate of $6,170,000,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Thermo Fisher Scientific hasn't issued any revenue guidance for the time being.Details Of The Call Date: Apr 22, 2020View more earnings on TMOTime: 12:02 PM ETWebcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.thermofisher.com%2Finvestors%2Fnews-and-events%2Fwebcasts-and-presentations%2Fevent-details%2F2020%2FQ1-2020-Thermo-Fisher-Scientific-Earnings-Conference-Call%2Fdefault.aspx&eventid=2159519&sessionid=1&key=FA407BA935D507E73CF497E24123BCE8®Tag=&sourcepage=registerPrice Action Company's 52-week high was at $342.26Company's 52-week low was at $250.21Price action over last quarter: Up 2.05%Company Overview Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (22% of sales); specialty diagnostic products (15%); life science solutions (27%); and lab products and services (42%).See more from Benzinga * STMicroelectronics: Q1 Earnings Insights * Recap: Ericsson Q1 Earnings * Afternoon Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.